Developments in oral enterotoxigenic Escherichia coli vaccines

Area of Science:

• Microbiology
• Vaccinology
• Infectious Diseases

Background:

• Enterotoxigenic Escherichia coli (ETEC) is a primary cause of diarrheal disease globally, particularly affecting children in developing nations and travelers.
• The World Health Organization (WHO) identifies ETEC as a critical vaccine target due to its significant public health impact.
• Currently, no licensed vaccine is available for ETEC prevention.

Purpose of the Study:

• To review and highlight recent advancements in the development of candidate vaccines against ETEC.
• To focus on promising oral vaccine strategies, including live, inactivated, and subunit approaches.
• To summarize the progress of these candidate vaccines in clinical and field trials.

Main Methods:

• Review of current research and development in ETEC vaccine technology.
• Analysis of candidate vaccines based on nontoxic enterotoxin and/or colonization factor antigens.
• Examination of data from clinical trials assessing safety, immunogenicity, and efficacy.

Main Results:

• Several promising ETEC vaccine candidates, including oral formulations, are under development.
• These candidates utilize various approaches such as live attenuated, inactivated, and subunit vaccines.
• Many candidates have demonstrated acceptable safety and immunogenicity profiles in clinical trials, with some showing protective efficacy in field or challenge studies.

Conclusions:

• Significant progress has been made in developing ETEC vaccines, with a focus on oral delivery systems.
• Candidate vaccines targeting key ETEC virulence factors show promise for future licensure.
• Further clinical evaluation is essential to confirm the protective efficacy of these ETEC vaccines.